Literature DB >> 32569519

HLAs, TCRs, and KIRs, a Triumvirate of Human Cell-Mediated Immunity.

Zakia Djaoud1, Peter Parham1.   

Abstract

In all human cells, human leukocyte antigen (HLA) class I glycoproteins assemble with a peptide and take it to the cell surface for surveillance by lymphocytes. These include natural killer (NK) cells and γδ T cells of innate immunity and αβ T cells of adaptive immunity. In healthy cells, the presented peptides derive from human proteins, to which lymphocytes are tolerant. In pathogen-infected cells, HLA class I expression is perturbed. Reduced HLA class I expression is detected by KIR and CD94:NKG2A receptors of NK cells. Almost any change in peptide presentation can be detected by αβ CD8+ T cells. In responding to extracellular pathogens, HLA class II glycoproteins, expressed by specialized antigen-presenting cells, present peptides to αβ CD4+ T cells. In comparison to the families of major histocompatibility complex (MHC) class I, MHC class II and αβ T cell receptors, the antigenic specificity of the γδ T cell receptors is incompletely understood.

Entities:  

Keywords:  HLA; KIR; TCR; haplotype; lymphocyte; polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32569519     DOI: 10.1146/annurev-biochem-011520-102754

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  16 in total

Review 1.  Unconventional T cells and kidney disease.

Authors:  Hannah Kaminski; Lionel Couzi; Matthias Eberl
Journal:  Nat Rev Nephrol       Date:  2021-08-26       Impact factor: 28.314

2.  KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.

Authors:  Matthew D Blunt; Andres Vallejo Pulido; Jack G Fisher; Lara V Graham; Amber D P Doyle; Rebecca Fulton; Matthew J Carter; Marta Polak; Peter W M Johnson; Mark S Cragg; Francesco Forconi; Salim I Khakoo
Journal:  J Immunol       Date:  2022-06-29       Impact factor: 5.426

3.  Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis.

Authors:  David J Margolis; Nandita Mitra; Ole J Hoffstad; Brian S Kim; Dimitri S Monos; Elizabeth J Phillips
Journal:  J Immunol       Date:  2021-08-18       Impact factor: 5.426

4.  Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.

Authors:  Maidul Islam; Britni M Arlian; Fabian Pfrengle; Shiteng Duan; Scott A Smith; James C Paulson
Journal:  J Am Chem Soc       Date:  2022-05-20       Impact factor: 16.383

5.  Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities.

Authors:  Fuguo Liu; Alexander T H Cocker; Jason L Pugh; Zakia Djaoud; Peter Parham; Lisbeth A Guethlein
Journal:  Immunogenetics       Date:  2022-05-13       Impact factor: 3.330

6.  Chickens as a simple system for scientific discovery: The example of the MHC.

Authors:  Clive A Tregaskes; Jim Kaufman
Journal:  Mol Immunol       Date:  2021-04-09       Impact factor: 4.407

Review 7.  Conformational sensing of major histocompatibility complex (MHC) class I molecules by immune receptors and intracellular assembly factors.

Authors:  Jie Geng; Malini Raghavan
Journal:  Curr Opin Immunol       Date:  2021-04-12       Impact factor: 7.268

8.  Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.

Authors:  Nayoung Kim; Dong-Hee Lee; Woo Seon Choi; Eunbi Yi; HyoJeong Kim; Jung Min Kim; Hyung-Seung Jin; Hun Sik Kim
Journal:  BMB Rep       Date:  2021-01       Impact factor: 4.778

Review 9.  From Chickens to Humans: The Importance of Peptide Repertoires for MHC Class I Alleles.

Authors:  Jim Kaufman
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

10.  Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia.

Authors:  Yu-Jun Dai; Si-Yuan He; Fang Hu; Xue-Ping Li; Jian-Ming Zhang; Si-Liang Chen; Wei-Na Zhang; Hai-Min Sun; Da-Wei Wang
Journal:  Mol Cancer       Date:  2021-01-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.